Novel HF pharmacotherapies such as ARNI and SGLT2 inhibitors were demonstrated to reduce cardiac mortality and HF hospitalizations and to promote cardiac reverse remodeling in HFrEF of both ischemic and non-ischemic etiology. This evidence concerns the gene SLC5A2 and hydrops fetalis.